Shenzhen Kangtai Biological Products Co., Ltd.
Symbole: 300601.SZ
SHZ
22.57
CNYPrix du marché aujourd'hui
33.5591
Ratio P/E
0.2598
Ratio PEG
24.02B
Cap MRK
- 0.01%
Rendement DIV
Shenzhen Kangtai Biological Products Co., Ltd. (300601-SZ) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1758.9 | 1458.4 | 3549.5 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 563.4 | 440.8 | 725.6 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 2819.2 | 2414.7 | 1991.2 | ||||||||||||
balance-sheet.row.inventory | 0 | 772.9 | 727.8 | 1058.2 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 45 | 573.9 | 741.7 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 5396 | 5174.9 | 7340.7 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 5756.9 | 5176.1 | 4116.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 2696.2 | 2041.3 | 99.4 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 630.3 | 708.3 | 558.6 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 101.7 | 210.6 | 1297.6 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 9689.4 | 8611.5 | 6808.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.account-payables | 0 | 791.2 | 434.1 | 708.2 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 174.3 | 273.7 | 800.1 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 25.9 | 173.4 | 98.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 2372.2 | 2015.7 | 1938 | ||||||||||||
Deferred Revenue Non Current | 0 | 328.7 | 383.1 | 349.5 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 1757.1 | 1600.8 | 2.8 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2463.6 | 2461.2 | 2364.1 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-liab | 0 | 5215 | 4801 | 4982.2 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 1116.9 | 1120.5 | 687.1 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 2216.7 | 1641.1 | 2435 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3117.4 | 3036 | 2417.5 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 3090.6 | 3187.7 | 3627.1 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 0 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 3259.6 | 440.8 | 99.4 | ||||||||||||
balance-sheet.row.total-debt | 0 | 2546.6 | 2289.4 | 2738.1 | ||||||||||||
balance-sheet.row.net-debt | 0 | 1351 | 1271.7 | -811.4 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -132.7 | 1263.4 | 679.2 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 200.9 | 404.7 | 92.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 10 | 30 | 104.8 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -604.5 | -275.6 | -461.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -488.8 | 273.9 | -796.5 | |||||||||||
cash-flows.row.inventory | 0 | 220.7 | -746.7 | -209.7 | |||||||||||
cash-flows.row.account-payables | 0 | -131 | 146.5 | 451.3 | |||||||||||
cash-flows.row.other-working-capital | 0 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 1277.6 | 179.2 | -68.6 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0.1 | 0.2 | 1227.7 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -3518 | -1100 | -2625 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2224.4 | 2198.2 | 13.7 | |||||||||||
cash-flows.row.other-investing-activites | 0 | -2.4 | 1.7 | -1226.7 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -2606.3 | -1440.3 | -3836.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | -1070.4 | -26.5 | -256 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 132.7 | -2.1 | -1 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | -20.6 | 2.1 | -0.2 | |||||||||||
cash-flows.row.dividends-paid | 0 | -622.2 | -220.4 | -207.3 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 1115.6 | 2699 | 4243.3 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -464.9 | 2452.2 | 3778.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -1.7 | -1 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | -2527.1 | 2663.1 | 381.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 994.1 | 3521.3 | 858.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3521.3 | 858.1 | 476.5 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 545.7 | 1652.3 | 439.8 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.free-cash-flow | 0 | -764.7 | -888.1 | -786.8 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 3451.8 | 3157.4 | 3652.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 622.8 | 499.9 | 986.4 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 2829.1 | 2657.5 | 2665.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 2054.2 | 2020.8 | 1071.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 2677 | 2520.8 | 2058.4 | ||||||||||||
income-statement-row.row.interest-income | 0 | 115.6 | 132.6 | 114.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 240.7 | 200.9 | 676.6 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 774.8 | 747 | 1452.2 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 940.3 | -338.2 | 1439.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 79 | -205.5 | 175.9 | ||||||||||||
income-statement-row.row.net-income | 0 | 861.3 | -132.7 | 1263.4 |
Questions fréquemment posées
Quel est le total de Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) de l'actif total?
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) Le total des actifs est 15085358535.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est N/A.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 0.832.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est 0.165.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est 0.224.
Quel est le revenu total de l'entreprise?
Le revenu total est 0.213.
Qu'est-ce que Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est 861303903.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 2546554090.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 2054244031.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 0.000.